Scientists from Cambridge University are working on a new urine test for early detection of lung cancer. The test is designed to find warning signs long before symptoms appear. The research was published in the journal Nature Aging. It was supported by Cancer Research UK funding. Scientists focused on special cells called senescent cells.
These cells are sometimes called zombie cells. They stop dividing but remain in the body. They also release harmful inflammatory signals. These signals can damage nearby tissue. They may also help cancer grow and spread. The scientists created an injectable sensor. This sensor reacts to proteins released by senescent cells.
When these proteins are detected, the sensor produces a signal. The signal can be measured in urine. This allows early signs of lung cancer to be identified. It may also show if treatment is working or failing. It could also help detect relapse earlier. The researchers tested the method using patient samples.
They also used large genetic data sets for confirmation. Lung cancer remains the leading cause of cancer death in the UK. About 32,800 people die from it each year. Survival depends strongly on how early it is diagnosed. Around 65 percent of patients survive five years if found early. In the late stages, survival drops to about five percent. Late detection accounts for nearly 46 per cent of cases in England. Because of this, early detection is very important. The new test aims to improve both diagnosis and treatment monitoring.
It may help doctors adjust therapy more quickly. It could also help identify patients at risk of resistance. The system works by producing a chemical marker in urine. This marker appears only when senescent cell activity is present. Researchers believe it could be used in clinics in the future. It has not yet been tested in humans. Clinical trials will be needed before it becomes widely available. Scientists say it may take several years to reach patients. Experts say this approach could improve survival rates in the future.
Researchers anticipate its implementation in GP surgeries and hospitals. Doctors say faster detection is critical for lung cancer care. The team confirmed findings using real patient data. The study marks a significant advancement in cancer research. Scientists believe it could help detect recurrence earlier. This could help tailor treatment to each patient. The work shows how tiny biological signals can reveal disease early. The goal is to improve survival and reduce late diagnosis. Researchers continue to move toward clinical trials in coming years. The sensor technology is based on nanotechnology principles. It is designed to react only in specific biological conditions.
This makes it highly sensitive to early disease changes. The researchers say it could complement existing screening methods. It is not intended to replace scans or biopsies. Instead, it could act as an early warning tool. Health experts say early diagnosis saves many lives. Delayed diagnosis often leads to limited treatment options. The test could also reduce pressure on hospitals. It may allow quicker decisions in primary care. Researchers are now planning larger clinical studies.
These studies will evaluate safety and effectiveness in humans. If successful, the test could become part of routine screening. The long-term goal is widespread use in healthcare systems. Scientists believe it could change how lung cancer is detected. The team also hopes the technology can be adapted for other cancers.
They believe similar senescent cell signals may exist in other diseases. Early detection is considered one of the most important goals in modern medicine. This approach could help doctors start treatment sooner and improve outcomes for patients.
Overall the research represents a promising step toward easier, cheaper and earlier cancer diagnosis in the future. However, more research and testing are still required before it becomes widely available to patients everywhere soon.
